Streetbeat News

Price Targets

UTHR

Over the past three months, 7 analysts have shared their evaluations of United Therapeutics (NASDAQ:UTHR), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased by 5.05% to $310.43. Analysts from firms like JP Morgan, Goldman Sachs, and Oppenheimer have raised their price targets, reflecting positive sentiment. Despite strong revenue growth, the company faces challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

May 21, 2024 | 5:00 pm

EXPE

BTIG analyst Jake Fuller maintains a Buy rating on Expedia Group (NASDAQ:EXPE) but lowers the price target from $175 to $150.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 4:59 pm

TGT

Target Corporation (NYSE:TGT) is set to report its Q1 earnings on May 22. Analysts expect revenue of $24.51 billion and earnings per share of $2.02. Target has a history of beating estimates, but recent price cuts on 5,000 items may impact results. Analysts have mixed ratings, with some seeing the stock dip as a buying opportunity.

Portfolio Pulse from Chris Katje

May 21, 2024 | 4:48 pm

NEXN

JMP Securities analyst Andrew Boone has reiterated a Market Outperform rating on Nexxen International (NASDAQ:NEXN) and maintained a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 4:39 pm

VLRS

JP Morgan analyst Fernando Abdalla maintains an Overweight rating on Controladora Vuela (NYSE:VLRS) and raises the price target from $17.5 to $18.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 4:39 pm

LRMR

JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Larimar Therapeutics (NASDAQ:LRMR) and maintained a $25 price target.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 4:37 pm

IFF

Morgan Stanley has downgraded Intl Flavors & Fragrances (NYSE:IFF) from Overweight to Equal-Weight, while maintaining a $100 price target.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 4:35 pm